Cronos Group Balans Gezondheid
Financiële gezondheid criteriumcontroles 6/6
Cronos Group heeft een totaal eigen vermogen van $1.1B en een totale schuld van $0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk $1.2B en $62.4M.
Belangrijke informatie
0%
Verhouding schuld/eigen vermogen
US$0
Schuld
| Rente dekkingsratio | n/a |
| Contant | US$797.02m |
| Aandelen | US$1.12b |
| Totaal verplichtingen | US$62.42m |
| Totaal activa | US$1.18b |
Recente financiële gezondheidsupdates
Analyse-artikel • May 31
We're Interested To See How Cronos Group (TSE:CRON) Uses Its Cash Hoard To Grow
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analyse-artikel • Mar 02
We Think Cronos Group (TSE:CRON) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analyse-artikel • Nov 09
Companies Like Cronos Group (TSE:CRON) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Recent updates
Narratiefupdate • Aug 09
CRON: Buybacks And Higher Multiple Will Support A Stronger Outlook
Analysts have increased their Cronos Group price target by CA$1 to CA$6, reflecting updated assumptions regarding fair value, discount rate, growth, and margins following recent research updates. What’s in the News for Cronos Group Cronos Group announced a share repurchase program that allows the company to buy back up to 18,712,918 shares for $50 million.Narratiefupdate • Jun 28
CRON: Partial Rescheduling And Buybacks Will Support A Stronger Outlook
Analysts have raised their Cronos Group price target by CA$0.50 to CA$5.50, citing revised assumptions around higher projected revenue growth, a different discount rate, and updated margin and P/E expectations following recent research commentary and a more favorable view on partial cannabis re scheduling. Analyst Commentary Recent research on Cronos Group highlights how shifting views on cannabis policy and updated valuation work are feeding into more constructive analyst sentiment on the stock.
Narratiefupdate • Jun 14
CRON: Brand Strength And Rescheduling Tailwinds Will Support Future Upside
Analysts have lifted their CA$ price target on Cronos Group, with an updated fair value of CA$4.68 compared with the prior CA$4.24. This reflects refreshed views on revenue growth, margins, discount rates and future P/E assumptions following recent Street research, including the CA$1 target increase at TD Securities and supportive commentary around partial cannabis rescheduling from Roth Capital.
Narratiefupdate • May 31
CRON: Partial Rescheduling Expectations Will Constrain Future Earnings Power
Analysts have raised Cronos Group's CA$ price target by CA$1, citing updated expectations around revenue growth, margins and future P/E assumptions, as well as recent Street research that includes a CA$1 target increase at TD Securities and favorable perspectives on partial cannabis re-scheduling. Analyst Commentary Recent Street commentary around Cronos Group has focused on how updated revenue expectations, margin trajectories and P/E assumptions feed into revised valuation frameworks.Narratiefupdate • May 12
CRON: Partial Rescheduling And Brand Execution Will Shape Lean Profit Outlook
Analysts have lifted their fair value estimate for Cronos Group from CA$3.19 to CA$3.45, citing recent initiation with a CA$4.50 price target and the view that branded positioning, a lean cost base, and potentially favorable regulatory shifts could support higher long term profitability and a lower future P/E assumption. Analyst Commentary Recent commentary around Cronos Group has focused on brand strength, cost discipline, and the potential impact of regulatory changes in key markets.Narratiefupdate • Apr 25
CRON: Partial Rescheduling Hopes Will Test Lean Cost Base Execution
Analysts have raised their Cronos Group price target to CA$4.50, citing expectations for slightly stronger revenue growth, modestly better profit margins, and a lower assumed future P/E, following recent bullish coverage and a favorable view on partial cannabis rescheduling. Analyst Commentary Recent research coverage on Cronos Group has centered on how potential regulatory shifts and brand positioning could influence the company’s path to improved profitability and valuation.Narratiefupdate • Apr 11
CRON: Canadian Brand Strength And Lean Cost Base Will Support Future Upside
Analysts have reset their price target for Cronos Group to CA$4.50, reflecting fresh coverage that highlights the company’s established Canadian brands, its focus on scaling revenue with a lean cost base, and cultivation practices that are expected to support profitability trends. Analyst Commentary Recent coverage frames Cronos Group as a company with established Canadian brands and a focus on keeping its cost base lean while scaling revenue.Narratiefupdate • Mar 28
CRON: Lean Cost Base And Brand Execution Will Shape Future Earnings Potential
Analysts have lifted their average price target for Cronos Group to CA$4.50, citing expectations for faster top line expansion, a leaner cost base and stronger profitability potential supported by the company's established Canadian cannabis brands and cultivation practices. Analyst Commentary Recent Street research has framed Cronos Group as a branded cannabis operator with established products in Canada and an emphasis on scaling revenue while keeping operating costs in check.Narratiefupdate • Mar 13
CRON: Canadian Brand Strength And Rescheduling Shift Will Support Future Upside
Analysts have lifted their CA$ price target on Cronos Group, citing the company's Canadian cannabis brands, expectations for better profitability as revenue grows against a lean cost base, and confidence in its cultivation practices as key supports for the higher valuation range. Analyst Commentary Bullish Takeaways Bullish analysts highlight Cronos Group's portfolio of Canadian cannabis brands as a key support for the higher CA$ valuation range, arguing that strong consumer recognition can help sustain revenue as the company scales.Narratiefupdate • Feb 27
CRON: Canadian Brand Strength And Rescheduling Shift Will Reshape Risk Reward Profile
Analysts have lifted their fair value estimate for Cronos Group to CA$4.24 from CA$3.95, pointing to higher assumed revenue growth and a lower future P/E multiple. They are factoring in recent bullish coverage highlighting the company’s established Canadian cannabis brands, lean cost base, and cultivation practices.Narratiefupdate • Feb 13
CRON: Rescheduling Shift Will Expose Execution Risks And Restrain Earnings Upside
Analysts have lifted their CA$ fair value estimate for Cronos Group to CA$3.19, citing Street research that points to slightly higher expected revenue growth, modestly stronger profit margins, and a marginally lower future P/E assumption that together support a more constructive long term outlook. Analyst Commentary While the higher CA$3.19 fair value estimate reflects a more constructive stance on Cronos Group, not all research is leaning in the same direction.Narratiefupdate • Jan 30
CRON: Rescheduling Shift And Product Expansion Will Shape A Balanced Earnings Outlook
Analysts have raised their price target on Cronos Group by a small amount to reflect updated assumptions for slightly higher revenue growth, a modestly stronger profit margin, and a marginally higher future P/E multiple. Analyst Commentary While some research points to a constructive view on Cronos Group, bearish analysts highlight a set of risks that could limit upside and keep the stock more range bound.Narratiefupdate • Jan 16
CRON: Rescheduling Policy Shift Will Temper Optimism On Future Earnings Profile
Analysts have raised their price target for Cronos Group to US$3.19 from US$2.90, pointing to updated assumptions around slightly higher discount rates, more conservative revenue growth and a modestly stronger profit margin profile, alongside a similar forward P/E outlook. What's in the News President Trump directed the Attorney General to complete the rulemaking process to reschedule marijuana to Schedule III of the Controlled Substances Act, which directly touches U.S. cannabis policy and mentions Cronos Group among other publicly traded peers in the sector (Marijuana Herald).Analyse-artikel • Dec 13
Cronos Group Inc. (TSE:CRON) Stock Rockets 29% As Investors Are Less Pessimistic Than Expected
Cronos Group Inc. ( TSE:CRON ) shareholders have had their patience rewarded with a 29% share price jump in the last...Narratiefupdate • Sep 04
GrowCo Capacity And Global Markets Will Unlock Potential
The Consensus Analyst Price Target for Cronos Group has increased to CA$3.95, primarily reflecting a notable rise in the company's Future P/E multiple despite stable revenue growth expectations. What's in the News President Trump is considering reclassifying marijuana as a less dangerous drug, which could ease restrictions and benefit cannabis companies such as Cronos Group (The Wall Street Journal).Analyse-artikel • Aug 15
Cronos Group Inc.'s (TSE:CRON) 26% Share Price Surge Not Quite Adding Up
Cronos Group Inc. ( TSE:CRON ) shareholders would be excited to see that the share price has had a great month, posting...
Nieuw narratief • Apr 30
GrowCo Expansion Will Boost Operations But Strain Cash Flow
Investment in GrowCo and advancements in cannabis genetics are set to improve efficiency, enhance profitability, and strengthen market penetration.Analyse-artikel • May 31
We're Interested To See How Cronos Group (TSE:CRON) Uses Its Cash Hoard To Grow
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analyse-artikel • Apr 01
Cronos Group Inc.'s (TSE:CRON) P/S Is Still On The Mark Following 29% Share Price Bounce
The Cronos Group Inc. ( TSE:CRON ) share price has done very well over the last month, posting an excellent gain of...Analyse-artikel • Mar 02
We Think Cronos Group (TSE:CRON) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analyse-artikel • Feb 02
Revenues Tell The Story For Cronos Group Inc. (TSE:CRON)
When you see that almost half of the companies in the Pharmaceuticals industry in Canada have price-to-sales ratios (or...Analyse-artikel • Nov 09
Companies Like Cronos Group (TSE:CRON) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( $912.0M ) CRON } overtreffen de korte termijn passiva ( $56.4M ).
Langlopende schulden: De kortetermijnactiva CRON ( $912.0M ) overtreffen de langetermijnschulden ( $6.1M ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: CRON is schuldenvrij.
Schuld verminderen: CRON had 5 jaar geleden geen schulden.
Schuldendekking: CRON heeft geen schulden en hoeft daarom niet gedekt te worden door de operationele kasstroom.
Rentedekking: CRON heeft geen schulden, dus de dekking van rentebetalingen is geen probleem.
Balans
Ontdek gezonde bedrijven
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/09/09 07:08 |
| Aandelenkoers aan het einde van de dag | 2026/09/09 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Cronos Group Inc. wordt gevolgd door 16 analisten. 4 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Jesse Pytlak | ATB Cormark Historical (Cormark Securities) |
| Vahan Ajamian | Beacon Securities Limited |
| Nadine Sarwat | Bernstein |